ENVALITH
H.U.グループホールディングス株式会社 logo

H.U. Group Holdings, Inc.

4544・Prime Market・Services

Official website
H.U.グループホールディングス株式会社 logo
H.U. Group Holdings, Inc.4544

Business

H.U. Group Holdings is a holding company with three business segments: Contract Clinical Laboratory Testing (LTS), In Vitro Diagnostics manufacturing and sales (IVD), and Healthcare-related Services (HS). In the LTS business, SRL, Inc. serves as the core operating company, providing contract testing services for Specialty & Routine Testing to a wide range of medical institutions, from large hospitals to clinics. In the IVD business, the company supplies in vitro diagnostic reagents domestically and internationally through Fujirebio Holdings, centered on the fully automated chemiluminescent enzyme immunoassay system Lumipulse®. In the HS business, the company operates Sterilization & Surgery-related Services through Nihon Steri Service, as well as home care services such as visiting nursing. Consolidated net sales for FY2026 (ending March 2026) were ¥247,362 million.

Business Model

The LTS business, which receives outsourced specimen testing from medical institutions, forms a stable revenue base, while the IVD business expands sales of its in-house developed reagent "Lumipulse®" to LTS customers, simultaneously achieving cost reduction through in-house reagent production and improved profit margins. Furthermore, through the CDMO business, the company supplies raw materials and contract manufacturing to global pharmaceutical and diagnostics companies, while the HS business supplements stable earnings through continuous contracts for sterilization and surgical support. Through integrated group management, the company aims to simultaneously introduce new test items and establish them as de facto standards.

Company Strengths

One of the few domestic corporate groups holding both contract clinical laboratory testing (LTS) and IVD manufacturing (IVD) within the same group. This structure enables accelerated market de facto standardization by preferentially introducing IVD-developed reagents to LTS customers, and in FY2026 (ending March 2026) the company continues to expand the introduction of Lumipulse® items to SRL. This is a vertically integrated model that is difficult for competitors to replicate in the short term.

Fujirebio's pTau217 and β-amyloid 1-42 assay reagents received the world's first FDA approval as blood-based in vitro diagnostics in May 2025. In Europe, CE marking has already been obtained for the NfL assay reagent. In Japan as well, a manufacturing and marketing approval application was filed in November 2025, establishing a track record of technological first-mover advantage in the NEURO field.

The H.U. Bioness Complex, centered on the Akiruno Lab, has been in full operation since the first quarter of FY2026 (ending March 2026). The automated testing line on the first floor has established an efficient profit-generating structure through automation and labor savings, resulting in a significant improvement in LTS business operating profit from a loss of ¥4,638 million in the previous period to a profit of ¥31 million. Improved fixed-cost absorption rates and enhanced testing operations have been confirmed as achieved results.

ENVALITH's Perspective

Operating profit for FY2026 (ending March 2026) improved substantially to ¥4,780 million (up 81.0% year on year), but ordinary profit remained subdued at ¥2,834 million (down 40.2% year on year). The main causes were the absence of the ¥3,070 million gain on investment fund management recorded in the previous period and an equity-method investment loss of ¥904 million. Profit attributable to owners of parent of ¥6,823 million (up 147.1% year on year) depended on extraordinary gains—a ¥2,290 million gain on sale of fixed assets and a ¥3,928 million gain on sale of shares in affiliated companies—and investors should scrutinize the point that the underlying strength on an ordinary profit basis remains at a low level.

Operating profit in the In Vitro Diagnostics Business declined to ¥9,050 million (down 20.2% year on year). This reflected sluggish performance in the CDMO business amid changes in the overseas market environment, a decline in revenue from COVID-19-related products, and costs associated with the acquisition of Plasma Services Group. While growth in NEURO-related products continues, the timing of the CDMO business's recovery and the outlook for product mix improvement are key variables that will determine whether the FY2027 (ending March 2026) [note: see correction below] earnings forecast (operating profit of ¥9,000 million) can be achieved.

The consolidated earnings forecast for FY2027 (ending March 2027) shows an aggressive plan with revenue of ¥256,000 million (up 3.5% year on year) and operating profit of ¥9,000 million (up 88.3% year on year), while profit attributable to owners of parent is forecast to decline to ¥5,000 million (down 26.7% year on year). This is believed to mainly reflect the reversal of extraordinary gains recorded in FY2026 (ending March 2026) (a total of ¥6,218 million from gains on sale of fixed assets and gains on sale of shares in affiliated companies). The company plans to maintain an annual dividend of ¥125, which is expected to result in a high dividend payout ratio of 138.7%, raising questions about the sustainability of financial discipline, including its consistency with the DOE target of 6%.

Growth Strategy

Driving the medium-term plan "H.U. 2030" through a three-pronged approach of improving LTS profitability, expanding IVD globally, and establishing pre-symptomatic healthcare

Promoting the consolidation of testing operations leveraging the full-scale operation of the H.U. Bioness Complex, along with an increase in contribution margin through optimization of selling prices. In FY2026 (ending March 2026), LTS operating profit turned positive at ¥31 million (versus a loss of ¥4,638 million in the prior period), reflecting the effects of these initiatives in the figures. Further profitability improvement is targeted for FY2027 (ending March 2027).

Promoting full-scale rollout in the US market starting from FDA approval of the pTau217 Alzheimer's disease diagnostic reagent (obtained in May 2025). Regulatory progress is advancing across the three major regions: in Japan, an application for manufacturing and marketing approval was submitted to the Ministry of Health, Labour and Welfare (November 2025); in Europe, certification was obtained for the in vitro diagnostic medical device for NfL measurement. NEURO-related sales are growing, driven primarily by overseas markets.

Strengthening the raw material supply framework for the CDMO Business through the acquisition of Plasma Services Group, Inc. announced in June 2025. In FY2026 (ending March 2026), the CDMO Business trended weak and acquisition-related costs were incurred, but the aim is to stabilize raw material procurement and expand the business over the medium to long term. The focus is on the earnings contribution from FY2027 (ending March 2027) onward.

In December 2025, Carelex Co., Ltd. was made an equity-method affiliate, and in the home care business, Gaia Medicare Co., Ltd. was made a consolidated subsidiary in December 2024. Concentrating management resources on the highly profitable Sterilization & Surgery-related Services while simultaneously expanding the home care business. HS operating profit for FY2026 (ending March 2026) was flat at ¥1,759 million (down 1.0% year on year).

Maintaining a progressive dividend policy with a consolidated dividend on equity (DOE) ratio of 6% as the key KPI. In FY2026 (ending March 2026), share buybacks of ¥5,002 million were carried out, and at the Board of Directors meeting on May 14, 2026, a further share buyback was resolved. The annual dividend of ¥125 is planned to be maintained in FY2027 (ending March 2027) as well. The dividend payout ratio is expected to remain at a high level of 138.7% (FY2027 (ending March 2027) forecast).

Last updated: July 19, 2026